Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Organovo (ONVO) presents at Canaccord Genuity Medical Technology & Diagnostics Forum - Slideshow $ONVO
http://www.seekingalpha.com/article/4024663
Organovo to Present at 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum
SAN DIEGO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum in New York on Thursday, November 17th at 1:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast at http://www.organovo.com. The audio webcast will be archived for 90 days following the conference.
Show me that my investment in SGLB was a good decision!
Yes - Growth stocks will become Income stocks without innovation! This is what should set ONVO ahead of any other competition.
I found this statement from Murphy to be the most informative: Allow me to describe a few examples of our compelling growth opportunities. First, we believe we can double the addressable market for liver and kidney tissue services by adding metabolism studies to our menu of services. This requires near-term investment in equipment, such as a mass spectrometer and personnel.
Organovo Holdings' (ONVO) CEO Keith Murphy on Q2 2017 Results - Earnings Call Transcript $ONVO
http://www.seekingalpha.com/article/4019300
Hologic tops Street 4Q forecasts http://www.cnbc.com/id/104074101.
I do feel like we were a bit mislead hear, but will wait to hear the explanation.
If SGLB goes up a penny a day, I can make up my losses in market open 250 days. Let's go Sigma Labs! Show me some revenue!
Organovo announced their 3rd webinar for Sept 29th. You can register from their events web page:
http://organovo.com/about/news/upcoming-events/
Even better!
Keith Murphy is disposing of a few shares (1394 & $4.00). This is not a big deal to me.
Thanks for your technical analysis, it is insightful.
I cannot private reply, but did read your message. I am an Ohioan, although no longer living in Columbus. I am a fan of The Ohio State Buckeyes football.
Here's an excerpt from the article: “This demonstration of methotrexate-induced fibrosis in our liver model has become a strong driver of customer adoption,” said Paul Gallant, general manager, Organovo. “Having data that so clearly shows a capability that has been elusive in the past is very compelling, and we’re continuing to build a solid base of customers given the growing validation of ExVive Human Liver Tissue’s ability to demonstrate correlation with known clinical results.”
Organovo press release: Organovo and Collaborators Publish Data in Toxicological Sciences Demonstrating Power of 3D Bioprinted Human Liver Tissues in Modeling Drug-Induced Liver Injury Leading to Fibrosis
Here's the link:
http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-newsArticle&ID=2201472
Organovo to Test Pre-Clinical Drugs on Bio-Printed Kidney Tissue (found on LinkedIn)
http://www.xconomy.com/san-diego/2016/09/09/organovo-to-test-pre-clinical-drugs-on-bio-printed-kidney-tissue/
Yep, I saw that too.
Organovo SEC filing on Friday announced a 1.5M registration of Securities offered to employees pursuant to employee benefit plans: http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkJFUmlacGNHRm5aVDB4TVRFeE16UXdNaVp6ZFdKemFXUTlOVGM9JnR5cGU9MiZmbj1Pcmdhbm92b0hvbGRpbmdzSW5jX1M4XzIwMTYwODI2LnBkZg==
With the current 10 day average just shy of 10k, that would be nice!
100K shares traded a day would certainly help with liquidity to close the Bid-Ask spread that we are seeing now.
Richard Maroun 15k shares & 37K warrants
Kirk Malloy 7.5k shares & 18.5k warrants
Mark Kessel 15k shares & 37K warrants
Tamar Howson 7.5k shares & 18.5k warrants
James Glover 7.5k shares & 18.5k warrants
Robert Baltera 7.5k shares (~146k total now) & 18.5k warrants
Organovo Appoints Two New Members to Board of Directors
SAN DIEGO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that its board of directors has appointed two new members. Mark Kessel, co-founder and partner of Symphony Capital LLC, and Richard Maroun, executive partner at Frazier Healthcare Partners, will join Organovo’s board, effective today. The appointments increase the number of Organovo directors to seven.
“Mark and Rick bring tremendous capital markets, corporate governance, operational and strategic management expertise to our organization,” said Keith Murphy, chairman and chief executive officer, Organovo. “Their leadership experience across the life sciences sector adds to the strength of our already outstanding board, and I’m confident they’ll make significant contributions as we enter our next phase of commercial growth and build value for our shareholders. I’m grateful for their willingness to join the board at such an important time in our organizational development, as well as the ongoing support from all of our directors.”
With their addition to the board, Kessel will become a member of the Nominating and Corporate Governance Committee and the Science and Technology Committee, while Maroun will join the Audit and Compensation Committees.
Mark Kessel is a partner of Symphony Capital, LLC, a private equity firm he co-founded in 2002 that invests in biopharmaceutical company clinical development programs. He is also Of Counsel at Shearman & Sterling and a member of the firm’s capital markets group. Previously, from 1971 to 2001, Mr. Kessel held various roles at Shearman & Sterling, including as managing partner leading the international law firm’s day-to-day operations. He helped build the firm, serving as a leader in the healthcare, biopharmaceutical, agricultural biotech, high-tech, and financial services practices. He also established the firm’s San Francisco office, serving as its managing partner and turning it into the leader in M&A, capital markets, corporate governance, and intellectual property and licensing issues. Mr. Kessel has previously served on several public biopharmaceutical company boards.
Richard Maroun is an executive partner at Frazier Healthcare Partners, a private equity and venture capital firm specializing in healthcare-focused investments. Before joining Frazier in 2015, Maroun was senior vice president and general counsel of Aptalis Pharmaceuticals from 2012 to 2014. He has also held numerous senior executive roles for APP Pharmaceuticals, Abraxis BioScience and American BioScience Inc. Mr. Maroun has worked with major financial organizations and independent law firms, and has held both legal and financial positions with companies including Merrill Lynch, Deloitte & Touche and McDonough, Holland & Allen. Mr. Maroun currently serves on the board of Leiter’s Enterprises, a private portfolio company of Frazier Healthcare Partners, and the Board of Trustees of John Carroll University.
So we wait... For news before year-end. Government contracting is often affected by delays.
The call just ended & nobody asked any questions?!
Thanks SilverSmith! My sentiments spoken so eloquently.
Just posted on LinkedIn. I apologize if this has already been posted, as I haven't had a chance to catch up with the board today.
https://www.linkedin.com/hp/update/6169286041783070720
Buy buy NYSE, Hello NASDAQ!
A Form 25 regarding Organovo Holdings, Inc. has been filed with the United States Securities and Exchange Commission.
x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, Organovo Holdings, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
SA put out a poor translation of the CC. Here's an excerpt:
Edward Tenthoff
Great. Thank you very much for taking the question. Keith and everybody, congrats on a really good quarter and just continued moment. I am excited to see the initial disorders for the kidney product, I just wanted to see [indiscernible] in the launch, but can tell us any qualitative response that you’re getting from new customers?
I thought it was a great call. I'm glad to be a long time investor & pumped about the future for Organovo.
Mr Market doesn't appear too happy with the CFO selection on this down day for the three big boards.
Webinar Recording: Fibrosis Model Using 3D Liver Tissue
http://organovo.com/webinar2/
Organovo Announces Appointment of Craig Kussman as Chief Financial Officer
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced the appointment of Craig Kussman as chief financial officer, effective August 22, 2016.
“Craig is an accomplished executive with significant financial, operational and strategic expertise,” said Keith Murphy, CEO, Organovo. “Craig’s background as a CFO for life science and healthcare companies, which has included leading finance, administrative and corporate development functions, will be an asset to us as we enter our next phase of commercial development and growth. We are pleased to welcome Craig to our team and look forward to his contributions.”
Kussman was most recently the chief financial officer at Alphaeon Corporation, a lifestyle healthcare company. Prior to his current role, Kussman served as chief financial officer of XIFIN, Inc., a healthcare information technology firm. Kussman formerly served as chief financial officer and senior vice president of corporate development for Ascenta Therapeutics, a developmental stage biopharmaceutical company. Kussman has also held senior executive positions at Breach Security, Discovery Partners International, Inc., SYNAVANT Inc., Cognizant Corp., and IMS Health.
Basically a formality. Thanks!
I received this in an email an hour ago (not sure what it is for - hoping to find out more during the webinar today):
ALERT: New Organovo Holdings, Inc. SEC Filing
A Form EFFECT regarding Organovo Holdings, Inc. has been filed with the United States Securities and Exchange Commission.
http://www.mynewsdesk.com/in/pressreleases/research-providing-in-depth-analysis-on-the-3d-bioprinters-market-2023-credence-research-1492273
From the linked article:
"Market Competition Assessment -
According to market experts competition in 3D bioprinting market is low and barriers are high. Competition is low due to presence of niche opportunities in the healthcare industry and barriers are high because the research is very specialized and requires a significant amount of investment, usually by the government or private donors, while the risks to profitability remain very high. 3D Systems, Inc. and Stratasys Ltd. dominate the 3D printer applications in healthcare market. The other upcoming key players such as Organovo, Inc. and EnvisionTEC, Inc. are expected to be one of the leading players in 3D bioprinting market in the near future."
Murphy's statement within the press release gives the following rationale: "NASDAQ is home to many of the world’s most innovative biotechnology and healthcare companies and is a natural fit for Organovo,” said Keith Murphy, CEO, Organovo. “We believe that this move will work to the long-term benefit of our shareholders.”
Doing a little light reading to research the differences between the NYSE & NASDAQ to see if I can understand the rationale for the switch & thought some of the folks on the board would find it useful. Here is the link I used as a starting place for my research, which contains additional links:
http://www.investopedia.com/university/electronictrading/trading1.asp.
I'm not sure what the rationale is behind this move.
The best part of the announcement was the last statement:
Gallant continued, “With a robust sales footprint in place, and our ability to leverage the strong relationships we’ve built with core customers in the liver toxicology business, we’re confident that we’ve positioned ourselves for early success with the kidney tissue. We look forward to bringing this groundbreaking product to market in the coming months.”